Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | NCF1 | P14598 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.35 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.35 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25696339 | 0.82 | MCHR1 (0.46) | MCHR1KDM4EHSD17B10ALDH1A1NCF1 | |
| SCHEMBL28000913 | 0.78 | KDM4E (0.43) | KDM4ETSHRHTTHSD17B10HPGD | |
| SCHEMBL18952767 | 0.77 | KDM4E (0.42) | KDM4ETSHRHTTHSD17B10ALDH1A1 | |
| SCHEMBL18952831 | 0.77 | KDM4E (0.39) | KDM4ETSHRHTTHSD17B10ALDH1A1 | |
| SCHEMBL9607760 | 0.74 | NOS3 (0.52) | KDM4ETSHRHTTALDH1A1HIF1A | |
| SCHEMBL29883886 | 0.74 | NOS3 (0.52) | KDM4ETSHRHTTALDH1A1HIF1A | |
| SCHEMBL9810196 | 0.73 | MCHR1 (0.52) | MCHR1KDM4ETSHRHTTHSD17B10 | |
| SCHEMBL30002828 | 0.72 | KDM4E (0.60) | KDM4ETSHRHTTALDH1A1LMNA | |
| SCHEMBL27088325 | 0.72 | KDM4E (0.60) | KDM4ETSHRHTTALDH1A1LMNA | |
| SCHEMBL359862 | 0.71 | MCHR1 (0.50) | MCHR1KDM4ETSHRHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3848370-B1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2025-05-07 | — | — | EP | disclosed |
| CN-115448916-A | TYK2 inhibitor and application thereof | 林伯士拉克许米公司 | 2022-12-09 | — | — | CN | disclosed |
| CN-109952303-B | TYK2 inhibitor and application thereof | 林伯士拉克许米公司 | 2022-10-21 | — | — | CN | disclosed |
| EP-3526222-B1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI INC (US) | 2022-08-17 | — | — | EP | disclosed |
| US-20220073527-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-03-10 | — | — | US | disclosed |
| US-20220073527-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-03-10 | — | — | US | disclosed |
| US-11220508-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2022-01-11 | — | — | US | disclosed |
| US-11220508-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2022-01-11 | — | — | US | disclosed |
| US-11174265-B2 | — | — | 2021-11-16 | — | — | US | disclosed |
| US-11174265-B2 | — | — | 2021-11-16 | — | — | US | disclosed |
| US-10793574-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20190284194-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-09-19 | — | — | US | disclosed |
| US-20190284194-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-09-19 | — | — | US | disclosed |
| EP-3526222-A1 | TYK2 INHIBITORS AND USES THEREOF | Nimbus Lakshmi, Inc. (US) | 2019-08-21 | — | — | EP | disclosed |
| US-10323036-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-10323036-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-20180155349-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-07 | — | — | US | disclosed |
| US-20180155349-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-07 | — | — | US | disclosed |
| WO-2018071794-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2018-04-19 | — | — | WO | disclosed |
| WO-2018071794-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11220508-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | MCHR1 3186/4885KDM4E 391/4885TSHR 1652/4885 |
| US-10793574-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | MCHR1 3186/4885KDM4E 391/4885TSHR 1652/4885 |
| US-10323036-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | MCHR1 3186/4885KDM4E 391/4885TSHR 1652/4885 |
| US-20190284194-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | MCHR1 3186/4885KDM4E 391/4885TSHR 1652/4885 |
| US-11174265-B2 | — | TYK2, JAK2, JAK1 | MCHR1 3275/4885KDM4E 533/4885TSHR 2492/4885 |
| US-20180155349-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | MCHR1 3186/4885KDM4E 391/4885TSHR 1652/4885 |
| US-20220073527-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | MCHR1 3186/4885KDM4E 391/4885TSHR 1652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.